Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736105 | 0.86 | KMT2A (0.40) | KMT2APOLBGRIA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12976429 | 0.78 | LMNA (0.33) | KMT2AALDH1A1SMN1; SMN2HTTCA2 | |
| SCHEMBL3296405 | 0.78 | LMNA (0.33) | KMT2AALDH1A1SMN1; SMN2HTTCA2 | |
| SCHEMBL3433536 | 0.77 | GRIA1 (0.43) | KMT2APOLBGRIA1ALDH1A1HTT | |
| SCHEMBL469145 | 0.76 | POLB (0.30) | KMT2APOLB | |
| SCHEMBL4762362 | 0.76 | GRIA1 (0.46) | KMT2APOLBGRIA1ALDH1A1HTT | |
| Methane SCHEMBL4915158 | 0.75 | LMNA (0.32) | KMT2AALDH1A1HTTCA2ALOX15 | |
| SCHEMBL3043384 | 0.75 | POLB (0.44) | POLBALDH1A1HTTCA2MAPT | |
| SCHEMBL40975 | 0.75 | LMNA (0.35) | KMT2APOLBALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1235922 | 0.75 | CA1 (0.46) | POLBALDH1A1CA2MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | KMT2A 1949/4885POLB 3854/4885GRIA1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.